Login
Companies $MMED
$18.42 -$0.23 (1.23%) Pre-market
MiniMed Group, Inc. logo

MiniMed Group, Inc.

What Do They Do?

Builds integrated diabetes-management systems, including insulin pumps, glucose monitors, dosing software and services, for people with diabetes and their healthcare providers.

How Do They Make Money?

Sells pumps, pens, glucose monitors, consumables and software to individuals, distributors, healthcare providers and institutions worldwide; customers generally pay when products ship or are delivered. Training and care-management services are paid as delivered.

revenue
SegmentShareRevenue
Pumps
Sold outright

18%
Consumables
Sold outright

31%
CGM
Sold outright

50%
Other
Sold outright
1.5%

Who Are Their Customers?

Individuals, healthcare providers and institutions around the world buy diabetes-management products. In the United States, MiniMed sells mainly directly to patients and also through independent distributors; sales outside the United States vary by market.

Do Revenues Turn Into Profits?

No. It lost $333M in FY2026.

Operating income, FY2026
−6% of revenue
▼ −30% (Loss) vs FY2025 (−$146M, −5%)
Net income, FY2026
−11% of revenue
▼ −56% (Loss) vs FY2025 (−$213M, −8%)
Free cash flow, FY2026
−14% of revenue
▼ −692% (Loss) vs FY2025 (−$53M, −2%)

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q1 FY2027, the three months to Jul 31, 2026
Revenue
▲ +17%
vs $723M in Q1 FY2026
Net income
▲ Turned profitable
vs −$19M in Q1 FY2026
  • Nov 16, 2026 FDA clearance moves MiniMed Fit launch to Spring 2027 The company expects the clearance-related $162 million charge to lower fiscal 2027 adjusted EBITDA margin guidance to approximately 11.3%, from approximately 16%.
  • Oct 15, 2026 Medtronic completed its separation from MiniMed Medtronic exchanged its MiniMed stake in an offer to its shareholders and no longer owns MiniMed shares.
  • Sep 1, 2026 MiniMed raised fiscal 2027 organic revenue growth guidance The company raised its outlook to approximately 10.5%, from approximately 10%.
Revenue over time
Pumps Consumables CGM Other
$5B$2.5B$0

Who Do They Compete With?

Competes with Beta Bionics, Dexcom, Insulet, Sequel Med Tech, Tandem Diabetes Care, Ypsomed, and Medtrum

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support